{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:18:06Z","timestamp":1783678686201,"version":"3.55.0"},"reference-count":80,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Severe treatment-resistant asthma (STRA) in children is often sustained by type 2 inflammation and eosinophil-dependent airway disease that persists despite optimized inhaled therapy and the mitigation of modifiable factors. This review summarizes the clinical and translational evidence on monoclonal antibodies targeting the interleukin-5 (IL-5) axis (anti-IL-5 and anti-IL-5R\u03b1) available in pediatric severe asthma. PubMed\/MEDLINE was searched up to January 2026 for English-language studies in patients aged 0\u201318 years addressing mepolizumab and benralizumab, including randomized trials, high-quality observational studies, meta-analyses, and international guidance. Mepolizumab has the most robust pediatric data, showing consistent reductions in exacerbations and blood eosinophils, and improvements in symptom control and quality of life, with safety broadly comparable to adults. The pediatric evidence for benralizumab is more limited but shows rapid eosinophil depletion, improved outcomes in selected children, and acceptable safety; further trials are ongoing. Overall, IL-5\u2013directed biologics represent a key add-on option for carefully selected children with severe eosinophilic asthma, while pediatric-specific predictors of response, comparative effectiveness, and standardized long-term monitoring and stopping criteria remain priorities.<\/jats:p>","DOI":"10.3390\/cells15141246","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:46:47Z","timestamp":1783676807000},"page":"1246","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal Antibodies Directed Against IL-5 in the Treatment of Pediatric Asthma"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4601-7484","authenticated-orcid":false,"given":"Valentina","family":"Fainardi","sequence":"first","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Carbone","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico Vito","family":"Buono","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marialaura","family":"Menzella","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7710-6995","authenticated-orcid":false,"given":"Carlo","family":"Caffarelli","sequence":"additional","affiliation":[{"name":"Pediatric Clinic, Department of Medicine and Surgery, University of Parma, 43126 Parma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40272-025-00694-6","article-title":"Unveiling the Complexities of Pediatric Asthma Treatment: Evidence, Controversies, and Emerging Approaches","volume":"27","author":"Peroni","year":"2025","journal-title":"Pediatr. Drugs"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dharmage, S.C., Perret, J.L., and Custovic, A. (2019). Epidemiology of asthma in children and adults. Front. Pediatr., 7.","DOI":"10.3389\/fped.2019.00246"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.5644\/ama2006-124.291","article-title":"Diagnosis and management of problematic severe asthma","volume":"49","author":"Scotney","year":"2020","journal-title":"Acta Medica Acad."},{"key":"ref_4","first-page":"e2020055","article-title":"An approach to the management of children with problematic severe asthma","volume":"91","author":"Fainardi","year":"2020","journal-title":"Acta Biomed."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1080\/1744666X.2022.2093187","article-title":"Challenges in uncontrolled asthma in pediatrics: Important considerations for the clinician","volume":"18","author":"Andrenacci","year":"2022","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1056\/NEJMoa1513737","article-title":"Patterns of growth and decline in lung function in persistent childhood asthma","volume":"374","author":"McGeachie","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","unstructured":"Global Initiative for Asthma (2026, March 28). Global Strategy for Asthma Management and Prevention. 2025. Update 15 November 2025. Available online: https:\/\/ginasthma.org."},{"key":"ref_9","unstructured":"National Institute for Health and Care Excellence (NICE) (2024). Asthma: Diagnosis, Monitoring and Chronic Asthma Management (BTS, NICE, SIGN), National Institute for Health and Care Excellence (NICE)."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1002\/ppul.27218","article-title":"The new biologic drugs: Which children with asthma should get what?","volume":"59","author":"Hillson","year":"2024","journal-title":"Pediatr. Pulmonol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"190301","DOI":"10.1183\/20734735.0301-2019","article-title":"Measuring inflammation in paediatric severe asthma: Biomarkers in clinical practice","volume":"16","author":"Licari","year":"2020","journal-title":"Breathe"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.anai.2018.07.029","article-title":"Use of biomarkers to identify phenotypes and endotypes of severe asthma","volume":"121","author":"Carr","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.23736\/S0026-4806.21.07332-8","article-title":"Asthma phenotypes and endotypes in childhood","volume":"113","author":"Fainardi","year":"2022","journal-title":"Minerva Medica"},{"key":"ref_14","first-page":"118","article-title":"Understanding the immunology of asthma: Pathophysiology, biomarkers, and treatments for asthma endotypes","volume":"36","author":"Gans","year":"2020","journal-title":"Paediatr. Respir. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1440-1843.2006.00784.x","article-title":"Inflammatory subtypes in asthma: Assessment and identification using induced sputum","volume":"11","author":"Simpson","year":"2006","journal-title":"Respirology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1164\/rccm.202104-1040LE","article-title":"Fractional exhaled nitric oxide nonsuppression identifies corticosteroid-resistant type 2 signaling in severe asthma","volume":"204","author":"Couillard","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2301397","DOI":"10.1183\/13993003.01397-2023","article-title":"The airway epithelium: An orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma","volume":"63","author":"Russell","year":"2024","journal-title":"Eur. Respir. J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41590-025-02212-9","article-title":"The immunology of asthma","volume":"26","author":"Lambrecht","year":"2025","journal-title":"Nat. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S78049","article-title":"Benralizumab: A unique IL-5 inhibitor for severe asthma","volume":"9","author":"Tan","year":"2016","journal-title":"J. Asthma Allergy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1111\/all.16242","article-title":"Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma","volume":"79","author":"Rupani","year":"2024","journal-title":"Allergy"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jaci.2023.03.023","article-title":"Eosinophils promote effector functions of lung group 2 innate lymphoid cells in allergic airway inflammation in mice","volume":"152","author":"LeSuer","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000053590","article-title":"Interferon-gamma increases CD62L expression on human eosinophils","volume":"120","author":"Momose","year":"1999","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/cea.14153","article-title":"High proportion of inflammatory CD62L (low) eosinophils in blood and nasal polyps of severe asthma patients","volume":"53","author":"Matucci","year":"2023","journal-title":"Clin. Exp. Allergy"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.jaci.2022.03.025","article-title":"Eosinophil- mediated suppression and anti- IL- 5 enhancement of plasmacytoid dendritic cell interferon responses in asthma","volume":"150","author":"Schwartz","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cea.13014","article-title":"Features of asthma which provide meaningful insights for understanding the disease heterogeneity","volume":"48","author":"Deliu","year":"2018","journal-title":"Clin. Exp. Allergy"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.jaci.2012.01.059","article-title":"Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines","volume":"129","author":"Bossley","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jaci.2016.06.061","article-title":"Asthma phenotypes in innercity children","volume":"138","author":"Zoratti","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaci.2015.06.038","article-title":"Type 2 innate lymphoid cells in induced sputum from children with severe asthma","volume":"137","author":"Nagakumar","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"210150","DOI":"10.1183\/16000617.0150-2021","article-title":"Eosinophils and eosinophilic immune dysfunction in health and disease","volume":"31","author":"Jackson","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.jaip.2023.01.037","article-title":"Blood eosinophils for prediction of exacerbation in preschool children with recurrent wheezing","volume":"11","author":"Fitzpatrick","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/all.16500","article-title":"Point-of-Care blood eosinophils to predict preschool wheeze attacks","volume":"80","author":"Hillson","year":"2025","journal-title":"Allergy"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Nakagome, K., and Nagata, M. (2018). Involvement and possible role of eosinophils in asthma exacerbation. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.02220"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/cea.12767","article-title":"Impaired airway epithelial cell responses from children with asthma to rhinoviral infection","volume":"46","author":"Kicic","year":"2016","journal-title":"Clin. Exp. Allergy"},{"key":"ref_35","unstructured":"(2026, April 21). Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2021\/20211112153726\/anx_153726_it.pdf."},{"key":"ref_36","unstructured":"(2026, April 21). Available online: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160816135589\/anx_135589_it.pdf."},{"key":"ref_37","unstructured":"(2026, April 21). Available online: https:\/\/www.ema.europa.eu\/it\/documents\/product-information\/fasenra-epar-product-information_it.pdf."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1007\/s12325-025-03457-4","article-title":"Safety and Tolerability of Twice-Yearly Depemokimab in Patients with Asthma and Chronic Rhinosinusitis with Nasal Polyps: Pooled Results from SWIFT-1\/-2 and ANCHOR-1\/-2","volume":"43","author":"Jackson","year":"2026","journal-title":"Adv. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"SWIFT-1 and SWIFT-2 Investigators; SWIFT-1 Investigators; SWIFT-2 Investigators. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","volume":"54","author":"Gupta","year":"2019","journal-title":"Pediatr. Pulmonol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): A randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): A randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13223-019-0366-x","article-title":"Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma","volume":"15","author":"Yancey","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e70155","DOI":"10.1002\/jcph.70155","article-title":"Development of Pediatric Dosing for Mepolizumab in Severe Asthma Based on Extrapolation of Data from Adult Patients and a Phase II Open-Label Pediatric Trial","volume":"66","author":"Gupta","year":"2026","journal-title":"J. Clin. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","volume":"144","author":"Gupta","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1001\/jamapediatrics.2025.2044","article-title":"Inner City Asthma Consortium and Childhood Asthma in Urban Settings Network. Inflammatory Pathways in Residual Asthma Exacerbations Among Mepolizumab-Treated Urban Children: A Secondary Analysis of a Randomized Clinical Trial","volume":"179","author":"Altman","year":"2025","journal-title":"JAMA Pediatr."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"00709-2024","DOI":"10.1183\/23120541.00709-2024","article-title":"Severe Paediatric Asthma Collaborative in Europe: Real-world data on children on biologics","volume":"11","author":"Liu","year":"2025","journal-title":"ERJ Open Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1901874","DOI":"10.1183\/13993003.01874-2019","article-title":"Blood eosinophil count in the general population: Typical values and potential confounders","volume":"55","author":"Hartl","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(23)00004-8","article-title":"Differing effects of mepolizumab across the life course","volume":"11","author":"Bush","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jaci.2017.08.020","article-title":"TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status","volume":"141","author":"Wisniewski","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jaci.2024.01.031","article-title":"Activated sputum eosinophils associated with exacerbations in children on mepolizumab","volume":"154","author":"Wilson","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1111\/all.15909","article-title":"Blood CD62Llow inflammatory eosinophils are related to the severity of asthma and reduced by mepolizumab","volume":"78","author":"Vultaggio","year":"2023","journal-title":"Allergy"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1702536","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"100638","DOI":"10.1016\/j.jacig.2025.100638","article-title":"Real-world impact of mepolizumab on pediatric and adolescent patients with severe asthma","volume":"5","author":"Hernandez","year":"2025","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/02770903.2024.2303767","article-title":"Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: A single center experience","volume":"61","author":"Lim","year":"2024","journal-title":"J. Asthma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: A 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s13223-019-0348-z","article-title":"Outcomes following mepolizumab treatment discontinuation: Real-world experience from an open-label trial","volume":"15","author":"Ortega","year":"2019","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e090749","DOI":"10.1136\/bmjopen-2024-090749","article-title":"Treating severe paediatric asthma with mepolizumab or omalizumab: A protocol for the TREAT randomised non-inferiority trial","volume":"14","author":"Cornelius","year":"2024","journal-title":"BMJ Open"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/11584340-000000000-00000","article-title":"Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody","volume":"50","author":"Smith","year":"2011","journal-title":"Clin. Pharmacokinet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.clinthera.2016.07.010","article-title":"Long-term Efficacy and Safety of Mepolizumab in Patients with Severe Eosinophilic Asthma: A Multicenter, Open-label, Phase IIIb Study","volume":"38","author":"Lugogo","year":"2016","journal-title":"Clin. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2417184","DOI":"10.1080\/07853890.2024.2417184","article-title":"Long-term safety of mepolizumab for up to ten years in patients with severe asthma: Open-label extension study","volume":"56","author":"Pavord","year":"2024","journal-title":"Ann. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2004306","DOI":"10.1183\/13993003.04306-2020","article-title":"Novel mechanisms of action contributing to benralizumab\u2019s potent anti-eosinophilic activity","volume":"59","author":"Dagher","year":"2022","journal-title":"Eur. Respir. J."},{"key":"ref_67","unstructured":"(2026, May 15). Available online: https:\/\/salute.regione.emilia-romagna.it\/ssr\/strumenti-e-informazioni\/ptr\/piani-terapeutici-e-rmp-ptr."},{"key":"ref_68","unstructured":"(2026, May 20). Available online: https:\/\/www.nice.org.uk\/guidance\/ta565\/chapter\/1-Recommendations."},{"key":"ref_69","unstructured":"(2026, May 25). Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/paediatric-investigation-plans\/emea-001214-pip04-19-m01."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e14092","DOI":"10.1111\/pai.14092","article-title":"All TATE investigators. Benralizumab in children with severe eosinophilic asthma: Pharmacokinetics and long-term safety (TATE study)","volume":"35","author":"Wedner","year":"2024","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b2-agonists (SIROCCO): A randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): A randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2147\/JAA.S172338","article-title":"Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: Results from the Phase IIIb ALIZE trial","volume":"11","author":"Zeitlin","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: Pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir. Med."},{"key":"ref_76","unstructured":"(2026, April 28). Clinicaltrials.Gov. NCT06750289. Last Updated: 19 March 2026, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06750289."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"e70272","DOI":"10.1111\/pai.70272","article-title":"DOMINICA protocol: A study of benralizumab for severe eosinophilic asthma in children","volume":"37","author":"Guilbert","year":"2026","journal-title":"Pediatr. Allergy Immunol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/psp4.12160","article-title":"Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients with Asthma","volume":"6","author":"Wang","year":"2017","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_79","unstructured":"(2026, May 21). Available online: https:\/\/www.ema.europa.eu\/it\/documents\/product-information\/exdensur-epar-product-information_it.pdf."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/thoraxjnl-2011-201064","article-title":"Sputum inflammatory phenotypes are not stable in children with asthma","volume":"67","author":"Fleming","year":"2012","journal-title":"Thorax"}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1246\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:58:40Z","timestamp":1783677520000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/14\/1246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":80,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cells15141246"],"URL":"https:\/\/doi.org\/10.3390\/cells15141246","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}